EAEU GMP Inspection and Certification for Foreign Pharmaceutical Manufacturers

For a foreign pharmaceutical manufacturer, EAEU GMP compliance is not a certificate-purchasing exercise and it is not a separate administrative task that can safely be postponed until the end of a registration project. It is a site-level regulatory workstream that has to be aligned with the products to be registered, the actual manufacturing and testing operations performed at the site, the registration dossier, the inspection scope and the intended lifecycle of the portfolio.

The old distinction between a “Russian GMP conclusion” and an EAEU GMP certificate is no longer the correct planning model for new projects. Pharmaceutical manufacturing for the EAEU common market is assessed against the EAEU Good Manufacturing Practice Rules adopted by EEC Council Decision No. 77. Pharmaceutical inspections are conducted under the EAEU inspection rules adopted by Decision No. 83, as amended. In Russia, the Ministry of Industry and Trade remains the competent authority for EAEU GMP certification of human medicinal products, while the State Institute of Drugs and Good Practices performs inspections of foreign manufacturing sites.

The practical question is therefore not simply “Do we have GMP?”. It is:

Does the EAEU GMP status of the site cover the manufacturing operations required by the product dossier, and can the site demonstrate—during an EAEU inspection—that its pharmaceutical quality system and actual production practice support those operations consistently?

That question should be answered before the registration critical path is fixed.

EAEU GMP is a regulatory dependency, not an isolated certificate

EAEU GMP compliance interacts directly with medicinal-product registration, API-related manufacturing, manufacturing-site changes and post-approval lifecycle work.

Under the EAEU registration framework, the quality assessment covers the manufacturing chain described in the dossier. If expert assessment raises doubts about the reliability of manufacturing information, an inspection may be requested before marketing authorization is granted. Current EAEU guidance also confirms that an EAEU GMP certificate can serve as evidence of site compliance without reproducing a product-by-product list in the certificate itself, while the competent authority may still decide—based on manufacturing information in the dossier—that an inspection is required during registration or that the site should be included in an inspection plan after registration.

This distinction matters. The certificate is not a universal statement that every possible product and activity at a site has been assessed. It reflects the GMP status of the site for the dosage forms and manufacturing operations within its certified scope.

The underlying inspection is nevertheless planned against a defined operational and product context. The EAEU inspection rules use structured lists of manufacturing operations, dosage forms, quality-control activities and products manufactured or planned to be manufactured at the site. A company can therefore have a valid certificate and still face a scope problem if a future registration or variation relies on activities that are not adequately covered.

For portfolio planning, Pharegis treats GMP scope as a regulatory asset that must match both the current dossier and foreseeable lifecycle changes.

What an EAEU GMP certificate actually confirms

An EAEU GMP certificate confirms that, at the time of the relevant inspection, the inspected site was considered compliant with the EAEU GMP Rules for the activities stated in the certificate. Under the current inspection rules, the certificate can be valid for no more than three years from completion of the inspection; the period may be shortened on the basis of risk.

The scope can include, as applicable:

• sterile or non-sterile dosage-form manufacture;
• biological medicinal-product manufacture;
• primary and secondary packaging;
• quality-control testing;
• batch-release-related operations;
• certain import-related quality activities;
• activities related to pharmaceutical substances where applicable.

The correct scope is therefore an engineering task before it becomes an inspection task.

An application that is too narrow can leave a later registration or variation unsupported. An unnecessarily broad application can increase preparation complexity without creating useful regulatory value. The manufacturer should know which buildings, lines, dosage forms, operations, laboratories and outsourced steps need to be inside the programme and why.

For a multi-product site, the product list used in inspection planning should also be selected deliberately. Products are practical routes through the quality system: inspectors can follow materials, batch documentation, deviations, analytical controls, validation records, changes or release decisions through the site.

Start with scope mapping, not with the application form

Before filing, Pharegis expects the manufacturer to be able to answer six questions:

1. Which legal manufacturing entity and exact site address are to be inspected?
2. Which buildings, lines and laboratories support the EAEU products?
3. Which dosage forms and manufacturing operations must fall within the intended GMP scope?
4. Which products will support the inspection programme?
5. Which activities are outsourced, and where do quality responsibilities change hands?
6. Which current or planned EAEU registration dossiers depend on this site and scope?

This prevents a common failure mode: preparing a technically correct GMP dossier that does not correspond to the actual registration strategy.

A site may perform bulk manufacture while another facility performs packaging, release testing or other critical operations. A sterile or biological product may involve specialized operations across several facilities. A manufacturer may also be adding a line or transferring a product while the GMP application is being prepared. Each situation changes the inspection strategy.

The Site Master File must describe the site inspectors will actually see

The Site Master File is central to inspection preparation, but a polished document cannot compensate for a site that operates differently from the file.

The Site Master File, organization structure, licenses, premises descriptions, utilities, equipment, product flows, QC laboratories, warehouses, outsourced activities and quality-system responsibilities should tell the same story. Particular attention is needed after changes to equipment, cleanrooms, layouts, computerized systems, contractors or major CAPA programmes.

Those inconsistencies are highly visible because an inspector can move directly from a controlled document to the relevant room, person, record or electronic system.

Pharegis therefore uses the Site Master File as a map for the readiness audit: every material statement should be testable against the facility.

Preliminary GMP audit: reproduce the inspection logic before the inspectors arrive

A preliminary audit is most useful when it resembles the logic of a regulatory inspection rather than a generic corporate quality audit.

The audit plan should be built individually around the manufacturing site: number and type of production lines, dosage forms, production capacities, laboratories, utilities, outsourced operations and the specific products and manufacturing stages expected to fall within the official inspection scope. The objective is to test the systems the regulator is likely to trace, not to distribute equal attention across every SOP in the quality system.

For formal inspection readiness, an on-site preliminary audit is normally the stronger option because it allows the auditor to compare controlled documentation with actual premises, flows, equipment, practices and data-generation processes. A document-based review can still be valuable for an early gap assessment, application package, Site Master File, CAPA follow-up or targeted technical issue, but it cannot fully reproduce what inspectors will see on the floor.

A robust preliminary audit should combine:

• review of the Site Master File, licenses, organization and quality-system architecture;
• physical walkthroughs of manufacturing, warehousing, utilities and QC areas relevant to the inspection scope;
• product- and batch-based tracing through manufacturing and analytical records;
• review of deviations, OOS/OOT, complaints, recalls, CAPA, change controls and Product Quality Reviews;
• review of qualification, validation, cleaning and computerized-system evidence;
• interviews with the actual system owners who will meet the inspectors;
• dossier-to-floor comparison for the products declared for EAEU inspection;
• a test of document retrieval speed and the ability to provide controlled evidence under inspection conditions.

The resulting report should not merely list observations. Each significant gap should be linked to the applicable requirement—primarily the EAEU GMP Rules under Decision No. 77 and, where relevant, applicable pharmacopoeial or other regulatory provisions—and translated into a remediation action. For material findings, Pharegis expects the report to identify the risk, affected system or product, immediate containment where needed, recommended CAPA, evidence required for closure, responsible function and timing relative to the official inspection.

This produces a risk-ranked inspection readiness matrix, not a cosmetic “mock inspection score”. The purpose is to improve the pharmaceutical quality system and remove predictable failure points before they are observed by the regulator.

EAEU GMP readiness is a system test

An effective pre-inspection audit should not be a rehearsal in which employees learn expected answers. It should test whether the pharmaceutical quality system can produce evidence under inspection conditions.

The EAEU inspection programme follows the core GMP architecture: pharmaceutical quality system, personnel, premises and equipment, documentation, production, quality control, outsourced activities, complaints and recalls, and self-inspection. For APIs, the relevant EAEU GMP provisions for active substances also have to be considered.

A risk-based readiness assessment normally focuses on these interfaces:

Pharmaceutical quality system, deviations and CAPA

Management review, risk assessment, escalation and product-quality oversight should work in practice. Deviations should lead to credible root-cause analysis, product-impact assessment and proportionate corrective and preventive actions. Repeated deviations closed administratively are a stronger warning signal than an imperfectly formatted SOP.

Change control and regulatory impact

Manufacturing, analytical, facility, equipment, software and supplier changes should be assessed across validation, product quality and regulatory commitments. For EAEU products, the quality system should detect when a technical change also requires a dossier variation.

Validation, qualification and computerized systems

Process validation, cleaning validation, analytical validation or verification, equipment qualification and continued verification should form a coherent evidence chain. Computerized-system access, audit trails, backup, archival, interfaces and laboratory data governance should also be tested through real records rather than policy review alone.

Production and quality control

Material and personnel flows, line clearance, dispensing, environmental controls, cleaning, cross-contamination prevention and reconciliation should be evaluated against the actual product mix. QC readiness should cover specifications, test methods, OOS/OOT investigations, reference standards, reagents, stability programmes, chromatographic data review and method transfer.

Suppliers and outsourced activities

The quality unit should be able to demonstrate qualification, quality agreements, oversight and escalation for contract manufacturers, laboratories, API suppliers and other critical providers. Outsourcing an activity does not outsource regulatory responsibility.

Product Quality Review and lifecycle signals

Annual/product quality reviews should function as decision tools. Trends from deviations, complaints, stability, OOS, yield, environmental monitoring, supplier performance or changes should lead to visible action where appropriate.

The dossier-to-floor check is where regulatory and GMP expertise meet

A site can be internally GMP-compliant and still create regulatory risk if the process actually performed does not match the approved or submitted registration dossier.

The readiness review should therefore compare, where relevant:

• manufacturing formula and batch size;
• manufacturing process and critical process parameters;
• in-process controls and hold times;
• manufacturing and testing sites;
• specifications and analytical procedures;
• release and shelf-life limits;
• primary packaging and storage conditions;
• process validation strategy;
• outsourced manufacturing and testing.

This is especially important when a global dossier has accumulated changes over many years or when different markets received different post-approval updates.

The result should be a dossier-to-site discrepancy matrix: every difference should be classified as a documentation issue, a GMP remediation issue, a dossier variation issue, or a point requiring a regulatory decision before inspection.

That exercise differentiates inspection readiness from a generic GMP audit.

Inspection planning and timing

The inspection timeline should be built backwards from the regulatory event that depends on GMP status: a new registration, an API-related procedure, a manufacturing-site variation, a transfer, or certificate expiry.

The EAEU now applies explicit risk-based principles to inspection planning. In 2025 the Eurasian Economic Commission adopted Guidelines for Planning Pharmaceutical Inspections based on risk assessment. The Commission also advised manufacturers approaching expiry of the first wave of Union GMP certificates to apply for routine inspection at least six to nine months before expiry to protect continuity of supply.

For applications handled through Russia, the procedure has a separate administrative review and inspection-planning sequence. Those regulatory clocks are not the complete project timeline.

The real critical path starts earlier:

scope confirmation → GMP dossier → preliminary audit → remediation → scheduling → inspection logistics → inspection → report → CAPA response → CAPA assessment → certificate decision.

If readiness work begins only after an inspection date is offered, the project has already lost much of its risk-control margin.

On-site inspection is the planning assumption; remote inspection is exceptional

The broad COVID-era use of remote GMP inspections should not be treated as a normal alternative for a new foreign-site project. Routine planning should assume that the inspection team will travel to the manufacturing site and inspect the facility in person.

At the same time, the current consolidated Decision No. 83 still retains a legal mechanism for remote inspection in defined exceptional circumstances, including emergency or force-majeure situations that create a threat to inspectors. Current risk-based planning guidance may also support remote interaction in limited low-risk situations subject to the inspectorate’s decision. For that reason, it would be inaccurate to describe remote inspection as legally abolished.

For a manufacturer, the practical rule is simpler: do not build the registration or certificate timeline on the assumption that a remote inspection will be available. Prepare the site for an on-site inspection unless the inspectorate expressly decides otherwise.

Language and interpreters: a logistical issue that can determine inspection performance

Foreign manufacturers frequently underestimate the language workstream.

For Russia-led inspections, Pharegis plans professional pharmaceutical interpretation as part of the inspection infrastructure, not as an administrative convenience. In practical inspection work, inspectors frequently split into parallel streams—for example, one inspector may follow production, another quality control and another the pharmaceutical quality system. One interpreter cannot support several parallel inspections.

Our operating rule is therefore one qualified pharmaceutical interpreter per inspector. If the team consists of three inspectors, the site should plan three professional interpreters. The interpreters can be arranged by the manufacturing site or by Pharegis, but they must be familiar with GMP terminology, production and QC language, and the discipline of consecutive interpretation under inspection conditions.

Document readiness is equally important. Decision No. 83 requires the core inspection package submitted to the inspectorate to be available in Russian and/or the applicable state language as required. During the site visit, Pharegis also requires documents that may be requested by inspectors to be readily understandable in Russian or English. For manufacturers whose controlled documentation is primarily in Chinese or another language, this requires advance planning.

The site should identify and translate, as necessary, the documents most likely to be requested during inspection, including:

• Site Master File and organization/quality-system documents;
• key SOPs and policies;
• batch manufacturing and packaging records for selected products;
• specifications, analytical methods and validation/verification documents;
• deviations, OOS/OOT investigations, CAPA and change controls;
• qualification and validation protocols/reports;
• Product Quality Reviews;
• quality agreements and outsourced-activity documentation;
• computerized-system and data-integrity records where relevant.

The controlled source document does not need to stop being a Chinese-language document, but a Chinese-only record that cannot be interpreted or translated fast enough for the inspector is not operationally inspection-ready.

Preparing a foreign site for the inspection team

Requested SOPs, batch records, investigations, validation reports, qualification protocols, audit-trail evidence and quality agreements should be retrievable rapidly and under document control. The people who own each GMP system should be available to explain it directly.

Pharegis normally recommends establishing:

• a primary inspection room and controlled document flow;
• a back room for document retrieval and response coordination;
• an inspection coordinator with authority to route requests;
• named subject-matter experts for each GMP system;
• one professional pharmaceutical interpreter for each inspector;
• controlled bilingual terminology for critical processes;
• a log of inspector requests, documents supplied and open questions;
• escalation rules for issues that may affect the registration dossier or product status.

The objective is not to stage-manage the inspection. It is to prevent a compliant system from looking uncontrolled because information is late, inconsistent, poorly translated or unavailable when inspectors divide into parallel workstreams.

What inspectors test in practice

The programme is site-specific, but inspectors can move horizontally through several systems rather than review one SOP after another.

A deviation may lead to batch documentation, analytical data, equipment logs, change controls, CAPA effectiveness and management oversight. A laboratory record may lead to audit trails, reference standards and method validation. A process change may lead directly to the registration dossier and regulatory change-control process.

This is why inspection readiness cannot be reduced to a checklist. The systems have to remain coherent when the inspection team follows evidence across departments.

Findings and CAPA: the inspection is not over when the team leaves

Under the current EAEU inspection rules, the regulatory outcome depends both on what was observed and, where applicable, on the adequacy of the manufacturer’s response.

Production can be recognized as GMP-compliant where there are no findings, where there are no critical or major findings, or where all critical and major findings are resolved after assessment of the response. Unresolved critical or major findings, or failure to provide the required response within the prescribed process, can result in a conclusion of non-compliance.

A CAPA response should therefore not be a collection of promises.

For each significant finding it should establish:

observation → immediate containment → product/quality impact → root cause → systemic extent → corrective action → preventive action → owner → due date → evidence → effectiveness verification.

Pharegis reviews CAPA against the regulatory consequence as well as the wording of the observation. If the root cause reveals an unreported manufacturing change, dossier inconsistency, validation deficiency or broader data-integrity concern, the response strategy has to address those consequences explicitly.

Certificate issuance and lifecycle control

A positive inspection does not create a permanent GMP status. The EAEU certificate reflects the status of the site at inspection, applies to the activities in its scope and is valid for no more than three years from the end of inspection. Risk factors can justify a shorter period.

Changes between inspections matter. Examples include new manufacturing lines, higher-risk operations, major reconstruction, significant QC changes, product transfers, major computerized-system changes, serious recalls, or substantial changes in outsourced manufacturing or testing.

The question after each major change is not simply whether the certificate has expired. It is whether the existing GMP scope and underlying evidence remain adequate for the products that depend on the site.

Where EAEU GMP projects most often lose time

The recurring problems are usually created before the inspection visit:

• applying before inspection scope is reconciled with the product portfolio;
• treating the Site Master File as a writing exercise rather than a site map;
• discovering late that dossier and manufacturing reality have diverged;
• selecting inspection products without considering which quality systems they expose;
• carrying unresolved major remediation into the formal inspection window;
• assuming EU, PIC/S or another GMP history removes the need to prepare for the EAEU framework;
• underestimating document translation and the need for one interpreter per inspector;
• preparing people for questions but not testing record retrieval;
• writing CAPA around the inspector’s wording instead of the system failure;
• planning on a remote inspection instead of preparing for an on-site visit;
• waiting for certificate expiry before starting reinspection planning.

Each of these is controllable if GMP, CMC and registration planning are managed together.

What Pharegis manages in an EAEU GMP inspection project

Pharegis can support a defined workstream or coordinate the complete inspection programme. Typical deliverables include:

• GMP scope and portfolio map linking sites, dosage forms, operations and products;
• regulatory pathway and timing memo integrating GMP with registration or variation milestones;
• preparation and review of the GMP application dossier and Site Master File package;
• individualized preliminary GMP audit based on the site, lines, products and expected inspection scope;
• risk-ranked audit report with regulatory references and remediation recommendations;
• dossier-to-floor review against relevant registration dossiers;
• risk-ranked remediation plan before inspection;
• mock inspection and evidence-retrieval testing;
• translation planning for site documentation;
• coordination of communication with the competent authority and inspection organization;
• inspection scheduling and foreign-site logistics support;
• provision or coordination of one professional pharmaceutical interpreter per inspector;
• regulatory support during inspection;
• review and structuring of responses to observations;
• CAPA strategy and effectiveness-evidence review;
• follow-up through the certificate decision;
• impact assessment of findings on registration dossiers and lifecycle changes;
• reinspection planning before certificate expiry.

For manufacturers entering the EAEU without an established regional regulatory function, the GMP workstream can be integrated into the broader market-entry programme. For multinational organizations, Pharegis can act as a specialist local regulatory interface for an individual high-risk site, portfolio, remediation programme or inspection.

Discuss an EAEU GMP inspection project

The most useful time to assess GMP readiness is before the formal inspection clock becomes the dominant constraint.

For an initial assessment, prepare the manufacturing-site name and address, current GMP certificates and inspection history, Site Master File, intended EAEU products, dosage forms and manufacturing operations, current or planned EAEU registration status, major open quality-system remediation items and the target date by which GMP status is required.

Pharegis can then determine whether the immediate priority is scope correction, dossier preparation, preliminary audit, site remediation, dossier-to-floor reconciliation, inspection scheduling, translation/interpreter planning or CAPA strategy—and place the GMP workstream on the same critical path as the registration or lifecycle project it is intended to support.

The objective is not simply to pass an inspection. It is to establish an EAEU GMP position that remains usable for the products, sites and lifecycle decisions that depend on it.

Regulatory basis

• EEC Council Decision No. 77 of 3 November 2016 — Good Manufacturing Practice Rules of the Eurasian Economic Union, as amended.
• EEC Council Decision No. 83 of 3 November 2016 — Rules for Pharmaceutical Inspections, current consolidated framework including subsequent amendments.
• EEC Council Decision No. 127 of 19 August 2022 — major revision of the EAEU pharmaceutical-inspection rules.
• EEC Council Decision No. 74 of 4 July 2023 — procedure for pharmaceutical inspections using remote interaction in the exceptional cases allowed by Decision No. 83.
• EEC Council Decision No. 78 of 3 November 2016 — Rules for Marketing Authorization and Expert Examination of Medicinal Products for Human Use, current consolidated framework.
• EEC Recommendation No. 77 of 17 August 2022 — documents confirming GMP compliance of medicinal-product manufacturing sites for registration purposes.
• EEC Board Recommendation No. 27 of 14 October 2025 — risk-based Guidelines for Planning Pharmaceutical Inspections.

Regulatory status reviewed: August 2026.